Sclerose …. Hvad nu ?

  • Post author:
  • Post published:28. January 2025
  • Post category:Artikler
  • Post comments:0 Comments

30352598
For en nydianosticeret til multiple sclerose-holdet kan det være svært at finde en grimasse der kan passe: ”A hva´for noget. Du siger at det der sker med mig er lig med sclerose?” (og så 117 billeder der farer gennem hovedet på en som alle ender med det samme image af invaliden i kørestolen.) ”Det kan bare ikke passe. Der må være sket en fejl, en forveksling. Jeg er jo sund og rask og har bare et lille problem med.....
(more…)

Continue ReadingSclerose …. Hvad nu ?

Pressemeddelelse

Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. today announced study results showing that patients with early relapsing-remitting multiple sclerosis (RRMS) taking once-yearly cycles of alemtuzumab reduced their risk of relapse by 74 percent and the risk of sustained accumulation of disability by 71 percent compared to patients treated with the active comparator Rebif® (high-dose interferon beta-1a). Importantly, the mean disability of patients on alemtuzumab improved from baseline, whereas the mean disability of those on Rebif worsened. The treatment benefits of alemtuzumab were sustained for at least three years, even though the majority of alemtuzumab-treated patients were last dosed two years earlier. These results come from the final three-year analysis of a Phase 2 clinical study (CAMMS223) reported in the Oct. 23 issue of the New England Journal of Medicine. The study involved 334 patients who had not previously been treated for their disease.

(more…)

Continue ReadingPressemeddelelse

Tabletbehandling giver markant bedre og nemme

Merck Serono’s Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial •Two-year primary efficacy endpoint of CLARITY trial met: 58% relative reduction in annualized relapse rate in the low total dose treatment group and 55% in the high total dose treatment group •Submission for registration of cladribine tablets planned for mid-2009 •Cladribine tablets are the first oral investigational multiple sclerosis treatment to complete a two-year pivotal study

Continue ReadingTabletbehandling giver markant bedre og nemme

Test af RebiSmart

Results of RebiSmart™ User Trial Presented at 25th ECTRIMS Congress Show Broad Patient Acceptance of the New Electronic Delivery Device for Relapsing Multiple Sclerosis Treatment Rebif® • The majority of patients found the electronic multidose device “suitable” or “very suitable” for self-injection and rated the device functions as “easy” or “very easy” to use • RebiSmart™ has the potential to improve treatment adherence for multiple sclerosis patients

Continue ReadingTest af RebiSmart

Folderen

Jeg synes det er en helt fantastisk folder for den nydiagnosticerede. Dem henvender sig i billeder, hvilket for de fleste er langt stærkere end "bare" tekst. Billederne, efter min mening…

Continue ReadingFolderen

Træning

Fysiotrapeutens hjørneFysioterapi kan gøre en forskel for den scleroseramte.Nøgleordet er træning.Det er en vigtigt faktor for opretholdelse og genoptræning af tabte funktioner efter attaks.Fysioterapeuter kan med deres viden om kroppen…

Continue ReadingTræning